MCID: SML019
MIFTS: 55

Smallpox

Categories: Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Smallpox

MalaCards integrated aliases for Smallpox:

Name: Smallpox 12 75 53 55 43 3 44 15 72 33
Ordinary Smallpox 12
Variola 53

Classifications:



External Ids:

Disease Ontology 12 DOID:8736
ICD9CM 35 050 050.9
MeSH 44 D012899
NCIt 50 C35027
SNOMED-CT 68 47452006 67924001
ICD10 33 B03
UMLS 72 C0037354

Summaries for Smallpox

MedlinePlus : 43 Smallpox is a disease caused by the Variola major virus. Some experts say that over the centuries it has killed more people than all other infectious diseases combined. Worldwide immunization stopped the spread of smallpox three decades ago. The last case was reported in 1977. Two research labs still keep small amounts of the virus. Experts fear bioterrorists could use the virus to spread disease. Smallpox spreads very easily from person to person. Symptoms are flu-like. They include High fever Fatigue Headache Backache A rash with flat red sores There is no treatment. Fluids and medicines for pain or fever can help control symptoms. Most people recover, but some can die. Those who do recover may have severe scars. The U.S. stopped routine smallpox vaccinations in 1972. Military and other high-risk groups continue to get the vaccine. The U.S. has increased its supply of the vaccine in recent years. The vaccine makes some people sick, so doctors save it for those at highest risk of disease.

MalaCards based summary : Smallpox, also known as ordinary smallpox, is related to variola major and viral infectious disease, and has symptoms including fever, pruritus and exanthema. An important gene associated with Smallpox is IL18R1 (Interleukin 18 Receptor 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Iron-Dextran Complex and Phenol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Variola virus, which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk.

CDC : 3 Before smallpox was eradicated, it was a serious infectious disease caused by the variola virus. It was contagious-meaning, it spread from one person to another. People who had smallpox had a fever and a distinctive, progressive skin rash. Most people with smallpox recovered, but about 3 out of every 10 people with the disease died. Many smallpox survivors have permanent scars over large areas of their body, especially their faces. Some are left blind. Thanks to the success of vaccination, smallpox was eradicated, and no cases of naturally occurring smallpox have happened since 1977. The last natural outbreak of smallpox in the United States occurred in 1949.

Wikipedia : 75 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Smallpox

Diseases related to Smallpox via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 variola major 34.5 IL2 IFNG
2 viral infectious disease 31.7 TNF IL4 IL2 IFNG
3 poliomyelitis 31.4 TNF IL4 IFNG
4 measles 31.2 IL4 IL2 IFNG
5 tetanus 31.1 IL4 IL2 IFNG
6 erythema multiforme 30.8 TNF IL2 IFNG
7 conjunctivitis 30.7 IL4 IL2 IFNG
8 gillessen-kaesbach-nishimura syndrome 30.6 IL18BP IL18
9 neuritis 30.6 TNF IL4 IFNG
10 severe combined immunodeficiency 30.5 IL4 IL2 IL18R1 IFNG
11 dermatitis, atopic 30.4 TNF IL4 IL2 IL18 IFNG
12 q fever 30.4 TNF IL4 IFNG
13 rubella 30.3 TNF IL4 IL12RB2
14 lymphadenitis 30.2 TNF IL18 IFNG
15 leishmaniasis 30.2 TNF IL4 IFNG
16 mumps 30.2 TNF IL2 IL12RB2 IFNG
17 leprosy 3 30.1 TNF IL2 IL12RB2 IFNG
18 contact dermatitis 30.1 TNF IL4 IFNG
19 cutaneous leishmaniasis 30.1 TNF IL4 IFNG
20 mycobacterium tuberculosis 1 30.1 TNF IL4 IL18 IFNG
21 toxoplasmosis 30.1 TNF IL4 IFNG
22 pleurisy 30.0 TNF IL2 IFNG
23 aphthous stomatitis 29.9 TNF IL4 IL2
24 toxic shock syndrome 29.9 TNF IL4 IL2 IFNG
25 acquired immunodeficiency syndrome 29.8 TNF IL2 IFNG CSF2
26 arthritis 29.8 TNF IL18 IFNG CSF2
27 nervous system disease 29.7 TNF IFNG CSF2
28 tonsillitis 29.7 TNF IL4 IL2 IFNG
29 autoimmune disease 29.7 TNF IL4 IL2 IFNG
30 schistosomiasis 29.7 TNF IL4 IL2 IFNG
31 pulmonary tuberculosis 29.6 TNF IL4 IL2 IL18 IFNG
32 lepromatous leprosy 29.6 TNF IL2 IL12RB2 IFNG
33 brucellosis 29.6 TNF IL4 IL2 IL18 IFNG
34 bacterial infectious disease 29.6 TNF IL18 IFNG CSF2
35 inflammatory bowel disease 29.6 TNF IL4 IL2 IL18 IFNG
36 crohn's disease 29.2 TNF IL18BP IL12RB2
37 sarcoidosis 1 29.1 TNF IL2 IL18 IFNG CSF2
38 asthma 29.0 TNF IL4 IL18R1 IL18 IFNG CSF2
39 cowpox 11.9
40 vaccinia 11.8
41 variola minor 11.7
42 monkeypox 11.6
43 obsolete: small pox 11.0
44 plague 10.7
45 yellow fever 10.7
46 cholera 10.7
47 epidemic typhus 10.7
48 dermatitis 10.7
49 encephalitis 10.6
50 hyperlucent lung 10.6 IL4 IFNG

Graphical network of the top 20 diseases related to Smallpox:



Diseases related to Smallpox

Symptoms & Phenotypes for Smallpox

UMLS symptoms related to Smallpox:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Smallpox:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 CSF2 GOLGA3 IFNG IL12RB2 IL18BP IL2
2 hematopoietic system MP:0005397 9.81 CSF2 IFNG IL12RB2 IL18 IL18BP IL18R1
3 homeostasis/metabolism MP:0005376 9.73 CSF2 CSMD1 GOLGA3 GPR158 IFNG IL12RB2
4 reproductive system MP:0005389 9.28 CSF2 GOLGA3 IFNG IL18BP IL2 IL4

Drugs & Therapeutics for Smallpox

Drugs for Smallpox (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron-Dextran Complex Phase 3
2
Phenol Approved, Experimental Phase 2 108-95-2 996
3
tannic acid Approved Phase 1, Phase 2 1401-55-4
4
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
5
rituximab Approved Phase 2 174722-31-7 10201696
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
8 Vaccines Phase 1, Phase 2
9 Immunologic Factors Phase 2
10 Antibodies Phase 2
11 Immunoglobulins Phase 2
12 Immunoglobulins, Intravenous Phase 2
13 gamma-Globulins Phase 2
14 Rho(D) Immune Globulin Phase 2
15 Thymoglobulin Phase 2
16 Antineoplastic Agents, Immunological Phase 2
17 Antilymphocyte Serum Phase 2
18 Isoantibodies Phase 2
19 Immunosuppressive Agents Phase 2
20 Antirheumatic Agents Phase 2
21
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
22
Metronidazole Approved Phase 1 443-48-1 4173
23 Pharmaceutical Solutions Phase 1
24 Anti-Infective Agents Phase 1
25 Anti-Bacterial Agents Phase 1
26 Adjuvants, Immunologic Phase 1
27 Keyhole-limpet hemocyanin Phase 1
28 Cathartics Phase 1
29 Gastrointestinal Agents Phase 1
30 Carboxymethylcellulose Sodium Phase 1
31 Laxatives Phase 1
32 Poly I-C Phase 1
33 interferons Phase 1
34 Poly ICLC Phase 1
35 Antiviral Agents Phase 1
36 Interferon Inducers Phase 1
37 Protective Agents Phase 1
38 Antibiotics, Antitubercular Phase 1
39 Radiation-Protective Agents Phase 1
40 polysaccharide-K Phase 1
41 diuretics Phase 1
42 Natriuretic Agents Phase 1
43 Androgens Phase 1
44 Hormones Phase 1
45 Hormone Antagonists Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
47 Antiparasitic Agents Phase 1
48 Antiprotozoal Agents Phase 1
49 Anti-Retroviral Agents Phase 1
50 Interferon-gamma

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
3 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Unknown status NCT01913353 Phase 3
4 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
5 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
6 Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
7 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
8 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects Completed NCT02474589 Phase 3 tecovirimat
9 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
10 An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP Completed NCT03161366 Phase 3
11 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Recruiting NCT03699124 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
14 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
15 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
16 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
17 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
18 Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. Completed NCT00258947 Phase 2
19 A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination Completed NCT00189904 Phase 1, Phase 2
20 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis Completed NCT00316602 Phase 2
21 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
22 A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00032708 Phase 2
23 Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects Completed NCT00189956 Phase 2
24 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
25 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
26 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
27 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
28 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
29 A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects Completed NCT00316524 Phase 2
30 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
31 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
32 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
33 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
34 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
35 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
36 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
37 A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery Completed NCT01827371 Phase 2
38 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
39 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
40 Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed NCT01266083 Phase 2
41 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
42 A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
43 A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth Completed NCT00679159 Phase 2
44 Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. Not yet recruiting NCT03681860 Phase 1, Phase 2
45 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study Terminated NCT00053508 Phase 2
46 Multi-Drug Desensitization Protocol for Heart Transplant Candidates Terminated NCT01556347 Phase 2 Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
47 The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination Completed NCT00079820 Phase 1
48 A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Immunogenicity and Protective Efficacy Against Dryvax® (Registered Trademark) Challenge in Vaccinia-Immune Individuals Completed NCT00053742 Phase 1 Modified Vaccinia Virus Ankara TBC-MVA
49 A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Dosing Schedule, Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive Individuals Completed NCT00046397 Phase 1 Modified Vaccinia Virus Ankara TBC-M
50 MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization Completed NCT00565929 Phase 1 Placebo

Search NIH Clinical Center for Smallpox

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cidofovir
Tecovirimat

Cochrane evidence based reviews: smallpox

Genetic Tests for Smallpox

Anatomical Context for Smallpox

MalaCards organs/tissues related to Smallpox:

41
Skin, T Cells, Testes, Prostate, Breast, Bone, Kidney

Publications for Smallpox

Articles related to Smallpox:

(show top 50) (show all 7446)
# Title Authors PMID Year
1
Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library. 38 17
30856707 2019
2
Atypical Cowpox Virus Infection in Smallpox-Vaccinated Patient, France. 38 17
30666929 2019
3
Medicolegal: Conditions Warranting Requirement of Vaccination. 17
31012919 2019
4
Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. 9 38
19104048 2008
5
Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. 9 38
17959666 2008
6
Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit. 9 38
16979683 2007
7
Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. 9 38
17141855 2007
8
Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. 9 38
17062140 2006
9
Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. 9 38
16185891 2005
10
Evolutionary history of orthopoxvirus proteins similar to human complement regulators. 9 38
16023794 2005
11
Identification of residues in an orthopoxvirus interleukin-18 binding protein involved in ligand binding and species specificity. 9 38
15193916 2004
12
Identification of the canarypox virus thymidine kinase gene and insertion of foreign genes. 9 38
10191193 1999
13
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. 38
31428674 2019
14
Rinderpest, smallpox, and the imperative of destruction. 38
31345445 2019
15
Evidence for Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence. 38
31369103 2019
16
The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. 38
31181284 2019
17
Intradermal Synthetic DNA Vaccination Generates Leishmania-Specific T Cells in the Skin and Protection against Leishmania major. 38
31182618 2019
18
Temporal and Spatial Dynamics of Monkeypox in Democratic Republic of Congo, 2000-2015. 38
31410720 2019
19
Genome of Alaskapox Virus, A Novel Orthopoxvirus Isolated from Alaska. 38
31375015 2019
20
Extended sequencing of vaccine and wild-type capripoxvirus isolates provides insights into genes modulating virulence and host range. 38
31379093 2019
21
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. 38
31426803 2019
22
The beginnings of smallpox vaccination in Spain seen through the correspondence of Ignacio María Ruiz de Luzuriaga (1801-1802). 38
31262586 2019
23
Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs. 38
31294846 2019
24
Childhood vaccination coverage in Europe: impact of different public health policies. 38
31268739 2019
25
Primary human B cells at different differentiation and maturation stages exhibit distinct susceptibilities to vaccinia virus binding and infection. 38
31292245 2019
26
Potential Viroporin Candidates From Pathogenic Viruses Using Bacteria-Based Bioassays. 38
31324045 2019
27
A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection. 38
30996093 2019
28
Neuroterrorism Preparedness for the Neurohospitalist. 38
31244972 2019
29
[Between vaccines, diseases, and resistances: the impacts of a smallpox epidemic in nineteenth-century Porto Alegre]. 38
31241674 2019
30
Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. 38
30853252 2019
31
Outbreak of Vaccinia Virus Infection from Occupational Exposure, China, 2017. 38
31107220 2019
32
Immunizations during pregnancy: How, when and why. 38
31226574 2019
33
Novel bioactive compound from the bark of Putranjiva roxburghii Wall. 38
31232117 2019
34
The beginning of smallpox vaccination in the Duchy of Parma. 38
31124993 2019
35
[Human poxvirus infections]. 38
31079914 2019
36
Fluorine-Containing Drugs Approved by the FDA in 2018. 38
31099931 2019
37
MC159 of Molluscum Contagiosum Virus Suppresses Autophagy by Recruiting Cellular SH3BP4 via an SH3 Domain-Mediated Interaction. 38
30842330 2019
38
HIV Vaccine Mystery and Viral Shell Disorder. 38
31072073 2019
39
Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-κB Activation and Inhibits CD8+ T-Cell Memory. 38
30814284 2019
40
Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. 38
30981594 2019
41
Synthetic biology for bioengineering virus-like particle vaccines. 38
30597533 2019
42
Cuban Public Health History: The 19th Century Board of Health in the City of Holguín. 38
31401639 2019
43
Cuban Public Health History: The 19th Century Board of Health in the City of Holguín. 38
31373587 2019
44
An HRM Assay to Differentiate Sheeppox Virus Vaccine Strains from Sheeppox Virus Field Isolates and other Capripoxvirus Species. 38
31040355 2019
45
A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. 38
30357851 2019
46
Preemptive Tecovirimat Use in an Active Duty Member Presenting with Acute Myeloid Leukemia after Smallpox Vaccination. 38
30959520 2019
47
[The organization of medical care in the mining and smelting okrugs of the Kama Vyatka region in the pre-reform period (end of XVIII-first half of XIX centuries)]. 38
30990994 2019
48
Measles and the Modern History of Vaccination. 38
30763141 2019
49
A Genealogy of Animal Diseases and Social Anthropology (1870-2000). 38
29572952 2019
50
The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo. 38
30567985 2019

Variations for Smallpox

Expression for Smallpox

Search GEO for disease gene expression data for Smallpox.

Pathways for Smallpox

Pathways related to Smallpox according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 UBE2D2 TNF IL4 IL2 IL18R1 IL18BP
2
Show member pathways
13.65 TNF IL4 IL2 IL18R1 IL18 IL12RB2
3
Show member pathways
13.52 TNF SPIRE1 IL4 IL2 IL18R1 IL18
4
Show member pathways
13.38 TNF IL4 IL2 IL18R1 IL18 IL12RB2
5
Show member pathways
13.3 TNF IL4 IL2 IL18R1 IL18BP IL18
6
Show member pathways
13.29 TNF IL4 IL2 IL18R1 IL18 IL12RB2
7
Show member pathways
12.84 TNF IL4 IL2 IL18R1 IL18 IL12RB2
8
Show member pathways
12.58 TNF IL2 IL18R1 IL18 IFNG
9
Show member pathways
12.56 TNF IL4 IL2 IL18R1 IL18 IL12RB2
10
Show member pathways
12.54 TNF IL4 IL2 IFNG CSF2
11 12.53 TNF IL4 IL2 IFNG
12
Show member pathways
12.5 TNF IL4 IL2 IFNG CSF2
13
Show member pathways
12.49 TNF IL4 IL2 IL18R1 IL18 IL12RB2
14
Show member pathways
12.39 IL4 IL2 IL12RB2 IFNG CSF2
15
Show member pathways
12.33 TNF IL4 IL2 IFNG
16
Show member pathways
12.32 TNF IL4 IFNG CSF2
17
Show member pathways
12.26 TNF IL4 IL2 IL18 IFNG
18
Show member pathways
12.22 TNF IL18R1 IL18BP IL18
19
Show member pathways
12.07 IL4 IL2 IL18R1 IL18 IFNG
20
Show member pathways
12.03 TNF IL4 IFNG CSF2
21 12 TNF IL4 IL2 IFNG
22 11.96 TNF IL4 IL2 IFNG CSF2
23 11.94 TNF IL4 IL18
24 11.93 TNF IL18R1 CSF2
25
Show member pathways
11.91 TNF IL2 IL18R1 IL18 IL12RB2 IFNG
26 11.89 TNF IFNG CSF2
27 11.87 TNF IL4 CSF2
28 11.86 TNF IL18 IFNG CSF2
29 11.84 IL2 IL12RB2 IFNG
30 11.8 IL4 IL2 IFNG CSF2
31 11.79 IL18 IFNG CSF2
32
Show member pathways
11.79 IL4 IL2 IL18R1 IL18 IL12RB2 IFNG
33 11.75 TNF IL2 IFNG CSF2
34 11.66 TNF IL4 CSF2
35
Show member pathways
11.65 TNF IL2 IFNG CSF2
36
Show member pathways
11.65 TNF IL4 IL2 IFNG CSF2
37
Show member pathways
11.64 TNF IL2 IFNG
38 11.56 TNF IL2 IFNG
39 11.54 TNF IL4 IL2 IL18 IL12RB2 IFNG
40 11.53 TNF IL18 IFNG
41 11.52 TNF IL18 IFNG
42 11.52 TNF IL2 IFNG
43 11.52 TNF IL4 IL18 CSF2
44 11.47 IL4 IL2 IL12RB2 IFNG
45 11.39 TNF IL18 IFNG
46 11.33 IL4 IL2 IFNG
47 11.28 TNF IL4 IL18 IFNG
48
Show member pathways
11.25 IL18R1 IL12RB2 IFNG
49 11.2 IL4 IL2 IFNG
50 11.2 TNF IL4 IL2 IL18 CSF2

GO Terms for Smallpox

Biological processes related to Smallpox according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 TNF IL4 IL18 IFNG CSF2
2 MAPK cascade GO:0000165 9.86 TNF IL2 IL18 CSF2
3 cytokine-mediated signaling pathway GO:0019221 9.8 TNF IL4 IL2 IL18 IL12RB2 CSF2
4 immune response GO:0006955 9.8 TNF IL4 IL2 IL18R1 IL18 IFNG
5 positive regulation of inflammatory response GO:0050729 9.76 TNF IL2 IL18
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.69 TNF IL18R1 IL18
7 positive regulation of T cell differentiation GO:0045582 9.64 IL4 IL2
8 myeloid dendritic cell differentiation GO:0043011 9.64 IL4 CSF2
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.63 IL18 CSF2
10 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2 IFNG
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 TNF IFNG
12 positive regulation of interleukin-17 production GO:0032740 9.62 IL2 IL18
13 positive regulation of podosome assembly GO:0071803 9.61 TNF CSF2
14 dendritic cell differentiation GO:0097028 9.59 IL4 CSF2
15 T-helper 1 type immune response GO:0042088 9.58 IL18BP IL18
16 natural killer cell activation GO:0030101 9.58 IL2 IL18R1 IL18
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.57 IL4 IL2
18 positive regulation of tissue remodeling GO:0034105 9.54 IL2 IL18
19 positive regulation of neuroinflammatory response GO:0150078 9.52 TNF IL18
20 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.49 IL18R1 IL18
21 positive regulation of interleukin-23 production GO:0032747 9.48 IFNG CSF2
22 type 2 immune response GO:0042092 9.46 IL4 IL18
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IFNG
24 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 IL4 IL2 IL18 IFNG CSF2
26 interleukin-18-mediated signaling pathway GO:0035655 9.33 IL18R1 IL18BP IL18
27 interferon-gamma production GO:0032609 9.3 IL12RB2
28 positive regulation of interferon-gamma production GO:0032729 9.02 TNF IL2 IL18R1 IL18 IL12RB2
29 negative regulation of transcription, DNA-templated GO:0045892 10.01 ZHX2 TNF IL4 IFNG CSF2

Molecular functions related to Smallpox according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL4 IL2 IL18 IFNG CSF2
2 interleukin-18 binding GO:0042007 8.96 IL18R1 IL18BP

Sources for Smallpox

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....